In cancer, while CD8+ CTLs are the primary effectors, Th1 cells enhance antigen presentation and activate cytotoxic CD8+ T cells, NK cells, and M1-like macrophages, fostering an effective antitumor response [40–43]. This evidence concerns the gene CD8A and cancer.